A higher incidence of conjunctivitis (up to 18% in one clinical trial) was observed with dupilumab therapy than with tralokinumab (2–6%)43 and lebrikizumab (6–13%)44, suggesting that IL-4 plays a role in conjunctivitis. This evidence concerns the gene IL4 and conjunctivitis.